+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antispasmodics Drugs Market Research Report by Drug type, Route of administration, End-User, Distribution Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5336389
  • Report
  • April 2022
  • Region: United States
  • 110 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • ACTIZA PHARMACEUTICAL
  • Allergan, Inc.
  • Aurobindo Pharma Limited
  • Fresenius Kabi AG
  • Lannett Company, Inc.
  • Mylan N.V.
The United States Antispasmodics Drugs Market size was estimated at USD 2,362.16 million in 2021, USD 2,684.42 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.09% to reach USD 4,206.44 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Antispasmodics Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug type, the market was studied across Dicyclomine hydrochloride, Hyoscyamine, and Loperamide hydrochloride.
  • Based on Route of administration, the market was studied across Injectable, Oral, and Sublingual.
  • Based on End-User, the market was studied across Hospitals and Speciality centres.
  • Based on Distribution Channel, the market was studied across Hospital pharmacy, Online pharmacy, and Retail pharmacy.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antispasmodics Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Antispasmodics Drugs Market, including ACTIZA PHARMACEUTICAL, Akorn Inc., Allergan, Inc., Ambrosia Pharma, Aurobindo Pharma Limited, B JOSHI AGROCHEM PHARMA, Blue Cross Laboratories Pvt Ltd., Daiichi Sankyo Company, Limited, Dr. Reddys Laboratories Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Lannett Company, Inc., LEXICARE PHARMA PVT. LTD., Mylan N.V., Nexus Pharmaceuticals Inc., RIPCORD PHARMACEUTICALS PVT. LTD., Shanghai Fosun Pharmaceutical Co., Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, SunGen Pharma LLC, and Wellona Pharma Private Limited..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Antispasmodics Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Antispasmodics Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Antispasmodics Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Antispasmodics Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Antispasmodics Drugs Market?
6. What is the market share of the leading vendors in the United States Antispasmodics Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Antispasmodics Drugs Market?
Frequently Asked Questions about the U.S. Antispasmodics Drugs Market

What is the estimated value of the U.S. Antispasmodics Drugs Market?

The U.S. Antispasmodics Drugs Market was estimated to be valued at $2362.2 Million in 2021.

What is the growth rate of the U.S. Antispasmodics Drugs Market?

The growth rate of the U.S. Antispasmodics Drugs Market is 10.0%, with an estimated value of $4206.4 Million by 2027.

What is the forecasted size of the U.S. Antispasmodics Drugs Market?

The U.S. Antispasmodics Drugs Market is estimated to be worth $4206.4 Million by 2027.

Who are the key companies in the U.S. Antispasmodics Drugs Market?

Key companies in the U.S. Antispasmodics Drugs Market include ACTIZA PHARMACEUTICAL, Akorn Inc., Allergan, Inc., Ambrosia Pharma, Aurobindo Pharma Limited, B JOSHI AGROCHEM PHARMA, Blue Cross Laboratories Pvt Ltd., Daiichi Sankyo Company, Limited and Fresenius Kabi AG.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ACTIZA PHARMACEUTICAL
  • Allergan, Inc.
  • Aurobindo Pharma Limited
  • Fresenius Kabi AG
  • Lannett Company, Inc.
  • Mylan N.V.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Antispasmodics Drugs Market, by Drug type
6.1. Introduction
6.2. Dicyclomine hydrochloride
6.3. Hyoscyamine
6.4. Loperamide hydrochloride
7. Antispasmodics Drugs Market, by Route of administration
7.1. Introduction
7.2. Injectable
7.3. Oral
7.4. Sublingual
8. Antispasmodics Drugs Market, by End-User
8.1. Introduction
8.2. Hospitals
8.3. Speciality centres
9. Antispasmodics Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital pharmacy
9.3. Online pharmacy
9.4. Retail pharmacy
10. California Antispasmodics Drugs Market11. Florida Antispasmodics Drugs Market12. Illinois Antispasmodics Drugs Market13. New York Antispasmodics Drugs Market14. Ohio Antispasmodics Drugs Market15. Pennsylvania Antispasmodics Drugs Market16. Texas Antispasmodics Drugs Market
17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion
18. Company Usability Profiles
18.1. ACTIZA PHARMACEUTICAL
18.2. Akorn Inc.
18.3. Allergan, Inc.
18.4. Ambrosia Pharma
18.5. Aurobindo Pharma Limited
18.6. B JOSHI AGROCHEM PHARMA
18.7. Blue Cross Laboratories Pvt Ltd.
18.8. Daiichi Sankyo Company, Limited
18.9. Dr. Reddys Laboratories Ltd.
18.10. Fresenius Kabi AG
18.11. Hikma Pharmaceuticals PLC
18.12. Lannett Company, Inc.
18.13. LEXICARE PHARMA PVT. LTD.
18.14. Mylan N.V.
18.15. Nexus Pharmaceuticals Inc.
18.16. RIPCORD PHARMACEUTICALS PVT. LTD.
18.17. Shanghai Fosun Pharmaceutical Co., Ltd.
18.18. Solitaire Pharmacia Private Limited
18.19. Strides Pharma Science Limited
18.20. SunGen Pharma LLC
18.21. Wellona Pharma Private Limited.
19. Appendix
19.1. Discussion Guide
19.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES ANTISPASMODICS DRUGS MARKET: DYNAMICS
FIGURE 2. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (%)
FIGURE 3. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2027
FIGURE 5. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, 2019-2027 (USD MILLION)
FIGURE 6. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 7. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, 2019-2027 (USD MILLION)
FIGURE 8. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 9. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, 2019-2027 (USD MILLION)
FIGURE 10. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 11. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 12. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2021 VS 2027 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 14. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, 2019-2027 (USD MILLION)
FIGURE 15. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 16. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, 2019-2027 (USD MILLION)
FIGURE 17. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 18. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, 2019-2027 (USD MILLION)
FIGURE 19. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 20. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 21. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2027
FIGURE 23. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD MILLION)
FIGURE 24. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, 2019-2027 (USD MILLION)
FIGURE 26. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 28. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 30. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 32. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2019-2027 (USD MILLION)
FIGURE 33. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 34. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 35. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 36. UNITED STATES ANTISPASMODICS DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 37. UNITED STATES ANTISPASMODICS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 38. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ANTISPASMODICS DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES ANTISPASMODICS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DRUG TYPE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DICYCLOMINE HYDROCHLORIDE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HYOSCYAMINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY LOPERAMIDE HYDROCHLORIDE, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTABLE, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY STATE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SUBLINGUAL, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END-USER, 2019-2027 (USD MILLION)
TABLE 12. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY SPECIALITY CENTRES, BY STATE, 2019-2027 (USD MILLION)
TABLE 14. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 15. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES ANTISPASMODICS DRUGS MARKET: SCORES
TABLE 19. UNITED STATES ANTISPASMODICS DRUGS MARKET: BUSINESS STRATEGY
TABLE 20. UNITED STATES ANTISPASMODICS DRUGS MARKET: PRODUCT SATISFACTION
TABLE 21. UNITED STATES ANTISPASMODICS DRUGS MARKET: RANKING
TABLE 22. UNITED STATES ANTISPASMODICS DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 23. UNITED STATES ANTISPASMODICS DRUGS MARKET: MERGER & ACQUISITION
TABLE 24. UNITED STATES ANTISPASMODICS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 25. UNITED STATES ANTISPASMODICS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 26. UNITED STATES ANTISPASMODICS DRUGS MARKET: INVESTMENT & FUNDING
TABLE 27. UNITED STATES ANTISPASMODICS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 28. UNITED STATES ANTISPASMODICS DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • ACTIZA PHARMACEUTICAL
  • Akorn Inc.
  • Allergan, Inc.
  • Ambrosia Pharma
  • Aurobindo Pharma Limited
  • B JOSHI AGROCHEM PHARMA
  • Blue Cross Laboratories Pvt Ltd.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddys Laboratories Ltd.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Lannett Company, Inc.
  • LEXICARE PHARMA PVT. LTD.
  • Mylan N.V.
  • Nexus Pharmaceuticals Inc.
  • RIPCORD PHARMACEUTICALS PVT. LTD.
  • Shanghai Fosun Pharmaceutical Co., Ltd.
  • Solitaire Pharmacia Private Limited
  • Strides Pharma Science Limited
  • SunGen Pharma LLC
  • Wellona Pharma Private Limited.
Note: Product cover images may vary from those shown

Loading
LOADING...